Scarica l'app Stockscreener
3.89
13.08%
0.45
Pre-mercato:
3.95
0.06
+1.54%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché IBIO Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$3.44
Aprire:
$3.41
Volume 24 ore:
2.16M
Relative Volume:
9.64
Capitalizzazione di mercato:
$38.41M
Reddito:
$2.05M
Utile/perdita netta:
$-23.15M
Rapporto P/E:
-0.5866
EPS:
-6.6319
Flusso di cassa netto:
$-16.93M
1 W Prestazione:
+5.71%
1M Prestazione:
+26.71%
6M Prestazione:
+91.63%
1 anno Prestazione:
+224.17%
Intervallo 1D:
$3.41
$4.37
Intervallo di 1 settimana:
$3.35
$4.37
Portata 52W:
$1.05
$4.98
iBio Inc Stock (IBIO) Company Profile
Nome
iBio Inc
Settore
Industria
Telefono
302-355-0650
Indirizzo
600 Madison Avenue, Suite 1601, New York, NY
Confronta IBIO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IBIO
iBio Inc
|
3.89 | 38.41M | 2.05M | -23.15M | -16.93M | -6.6319 |
|
VRTX
Vertex Pharmaceuticals Inc
|
480.35 | 123.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
723.47 | 79.09B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
624.94 | 37.97B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.20 | 31.74B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
259.70 | 27.71B | 3.32B | -860.46M | -1.04B | -8.32 |
iBio Inc Stock (IBIO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-05-28 | Iniziato | Chardan Capital Markets | Buy |
| 2021-11-29 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-01-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-06-26 | Iniziato | Alliance Global Partners | Buy |
iBio Inc Borsa (IBIO) Ultime notizie
iBio, Inc. Advances in Therapeutics and Leadership - TipRanks
iBio Inc. stock falls Friday, underperforms market - MarketWatch
iBio Inc. stock falls Thursday, underperforms market - MarketWatch
iBio to Begin Trading on the Nasdaq Stock Exchange - GlobeNewswire
iBio Inc. stock rises Wednesday, outperforms market - MarketWatch
iBio Announces Transfer to Nasdaq Capital Market - TipRanks
Can iBio's Nasdaq Move Transform Its Market Presence? Key Details Revealed - StockTitan
Is Ibio, Inc. (IBIO) Among Stocks Insiders Are Buying This Year? - Insider Monkey
10 Stocks Insiders Are Buying This Year - Insider Monkey
Ibio Inc Faces Financial Risk from Potential Stockholder Equity Dilution and Capital Raising Challenges - TipRanks
iBio Inc. stock falls Tuesday, underperforms market - MarketWatch
SEC Form 424B3 filed by iBio Inc. - Quantisnow
iBio Inc. stock falls Monday, underperforms market - MarketWatch
iBio Inc. (IBIO) reports earnings - Quartz
iBio, Inc. Reports Second Quarter Fiscal 2025 Financial Results and Corporate Updates on Advancements in Cardiometabolic Therapeutics - Nasdaq
iBio Reports Fiscal Second Quarter 2025 Financial Results - GlobeNewswire
IBIO's Strategic Pivot: AI-Powered Antibody Discovery Shows Promise Despite Q2 Losses - StockTitan
iBio Inc. stock rises Friday, outperforms market - MarketWatch
A Tale of Resilience: iBio Inc Amid Stock Market Turbulence - The InvestChronicle
iBio (IBIO) Projected to Post Quarterly Earnings on Friday - Defense World
iBio Inc. stock rises Thursday, outperforms market - MarketWatch
iBio Inc. stock rises Tuesday, outperforms market - MarketWatch
iBio (NYSE:IBIO) Trading Up 4% – Time to Buy? - Defense World
iBio (NYSEMKT:IBIO) Trading Up 1.3% – Still a Buy? - Defense World
iBio Inc. stock rises Monday, outperforms market - MarketWatch
iBio Inc. stock falls Monday, still outperforms market - MarketWatch
I: Weekly TechBio News - substack.com
iBio Announces Successful Closing of Private Placement OfferingOn January 10, 2025, iBio, Inc. (NYSE American: IBIO) announced the completion of a private placement offering, marking an important development for the company. The securities purchase a - Defense World
iBio director William Clark purchases $4,999 in common stock - Investing.com India
iBio director Parada acquires $499,998 in common stock By Investing.com - Investing.com Australia
iBio director William Clark purchases $4,999 in common stock By Investing.com - Investing.com Australia
Felipe Duran Increases Stake in iBio Inc with Recent Share Purch - GuruFocus.com
Director David Arkowitz Acquires 18,382 Shares of iBio Inc (IBIO) - GuruFocus.com
Insider Buying: Gary Sender Acquires 9,191 Shares of iBio Inc (I - GuruFocus.com
Ibio's chief legal officer Marc Banjak buys $24,999 in stock By Investing.com - Investing.com Australia
iBio director Gary Sender purchases $24,999 in common stock By Investing.com - Investing.com Australia
Ibio CEO Brenner Martin acquires $24,999 in stock By Investing.com - Investing.com Australia
Ibio's CFO Duran Felipe buys $24,999 in common stock By Investing.com - Investing.com Australia
iBio director Arkowitz purchases $49,999 in common stock By Investing.com - Investing.com Australia
Ibio’s CFO Duran Felipe buys $24,999 in common stock By Investing.com - Investing.com Nigeria
Ibio’s chief legal officer Marc Banjak buys $24,999 in stock By Investing.com - Investing.com Nigeria
iBio Inc Azioni (IBIO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.53%
0.33%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):